4.575

0.55% -0.005

Xeris Biopharma Holdings Inc (XERS)

Overview News Price History Option Chain Financials Discussions Forecast

Xeris Biopharma Holdings Inc stock is traded at $4.575, with a volume of 953.70K. It is down -0.55% in the last 24 hours and up +26.25% over the past month. Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).

Previous Close:

$4.57

Open:

$4.55

24h Volume:

953.70K

Relative Volume:

0.51

Market Cap:

$695.81M

Revenue:

$181.41M

Net Income/Loss:

$-59.56M

P/E Ratio:

-10.89

EPS:

-0.42

Net Cash Flow:

$-38.83M

1W Performance:

+10.05%

1M Performance:

+26.25%

6M Performance:

+57.81%

1Y Performance:

+108.49%

1-Day Range:

$4.49

$4.6793

1-Week Range:

$4.05

$4.68

52-Week Range:

$1.69

$4.68

Xeris Biopharma Holdings Inc Stock (XERS) Company Profile

Name

Xeris Biopharma Holdings Inc

Sector

Healthcare (1172)

Industry

Biotechnology (680)

Phone

844-445-5704

Address

1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL

Employee

394

Twitter

@XerisPharma

Next Earnings Date

2024-12-08

Latest SEC Filings

XERS's Discussions on Twitter

Compare XERS with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
XERS Xeris Biopharma Holdings Inc	4.565	695.81M	181.41M	-59.56M	-38.83M	-0.42
VRTX Vertex Pharmaceuticals Inc	500.60	130.96B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	682.70	75.53B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	578.37	35.07B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	241.17	31.72B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	249.50	26.76B	3.32B	-860.46M	-1.04B	-8.32

Xeris Biopharma Holdings Inc Stock (XERS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-11-24	Downgrade	Piper Sandler	Overweight → Neutral
Mar-28-24	Initiated	Oppenheimer	Outperform
Aug-28-23	Initiated	Craig Hallum	Buy
Oct-21-22	Initiated	Jefferies	Buy
Apr-28-22	Initiated	Craig Hallum	Buy
Nov-17-21	Initiated	SVB Leerink	Outperform
Oct-29-21	Initiated	H.C. Wainwright	Buy
Apr-07-21	Resumed	RBC Capital Mkts	Outperform
Feb-18-20	Initiated	Piper Sandler	Overweight
Jul-16-18	Initiated	Jefferies	Buy
Jul-16-18	Initiated	Leerink Partners	Outperform
Jul-16-18	Initiated	RBC Capital Mkts	Outperform

View All

Xeris Biopharma Holdings Inc Stock (XERS) Latest News

01:29 AM

Analysts Set Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Target Price at $5.92 - Defense World

01:29 AM

Mar 11, 2025

Will Xeris Biopharma's Financial Transformation Reach New Heights In 2025? - RTTNews

Mar 11, 2025

Xeris BiopharmaPossibly the best Pharma Stock - Inkl

Mar 11, 2025

Xeris Biopharma (XERS) Expects to Ride the Wave of 30% Revenue Growth in 2025 - Markets Insider

Mar 11, 2025

Mar 10, 2025

What Are Expectations For Xeris Biopharma Holdings Inc (NASDAQ: XERS) In The Short Term? - Stocks Register

Mar 10, 2025

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 10, 2025

Analysts Issue Forecasts for Xeris Biopharma Q1 Earnings - Defense World

Mar 10, 2025

Mar 09, 2025

Piper Sandler Reaffirms Neutral Rating for Xeris Biopharma (NASDAQ:XERS) - Defense World

Mar 09, 2025

Mar 08, 2025

Who Really Controls Xeris Biopharma? The Retail Investors’ Unseen Power - DSA

Mar 08, 2025

Principal Financial Group Inc. Grows Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World

Mar 08, 2025

Rhumbline Advisers Purchases 7,408 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World

Mar 08, 2025

Mar 07, 2025